CA2858427A1 - Procede de traitement du cancer par administration de faibles taux de proteine de choc thermique 70 (hsp70) - Google Patents

Procede de traitement du cancer par administration de faibles taux de proteine de choc thermique 70 (hsp70) Download PDF

Info

Publication number
CA2858427A1
CA2858427A1 CA2858427A CA2858427A CA2858427A1 CA 2858427 A1 CA2858427 A1 CA 2858427A1 CA 2858427 A CA2858427 A CA 2858427A CA 2858427 A CA2858427 A CA 2858427A CA 2858427 A1 CA2858427 A1 CA 2858427A1
Authority
CA
Canada
Prior art keywords
hsp70
tumors
carcinoma
administered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2858427A
Other languages
English (en)
Inventor
John Mcmichael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beech Tree Labs Inc
Original Assignee
Beech Tree Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beech Tree Labs Inc filed Critical Beech Tree Labs Inc
Publication of CA2858427A1 publication Critical patent/CA2858427A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2858427A 2012-01-05 2013-01-04 Procede de traitement du cancer par administration de faibles taux de proteine de choc thermique 70 (hsp70) Abandoned CA2858427A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261583535P 2012-01-05 2012-01-05
US61/583,535 2012-01-05
PCT/US2013/020252 WO2013103792A2 (fr) 2012-01-05 2013-01-04 Procédé de traitement du cancer par administration de faibles taux de protéine de choc thermique 70 (hsp70)

Publications (1)

Publication Number Publication Date
CA2858427A1 true CA2858427A1 (fr) 2013-07-11

Family

ID=48745538

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2858427A Abandoned CA2858427A1 (fr) 2012-01-05 2013-01-04 Procede de traitement du cancer par administration de faibles taux de proteine de choc thermique 70 (hsp70)

Country Status (6)

Country Link
EP (1) EP2800577A2 (fr)
JP (1) JP2015515445A (fr)
AU (1) AU2013207466A1 (fr)
CA (1) CA2858427A1 (fr)
IL (1) IL232732A0 (fr)
WO (1) WO2013103792A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202019398A (zh) * 2018-06-28 2020-06-01 張翔毓 用於治療或預防構形疾病之方法及藥物篩選方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59912185D1 (de) * 1998-03-27 2005-07-21 Multhoff Gabriele Verwendung von hsp70 protein
HUE025852T2 (en) * 2008-06-26 2016-04-28 Orphazyme Aps Use of HSP70 to regulate enzyme activity

Also Published As

Publication number Publication date
JP2015515445A (ja) 2015-05-28
AU2013207466A1 (en) 2014-06-12
WO2013103792A2 (fr) 2013-07-11
IL232732A0 (en) 2014-07-31
EP2800577A2 (fr) 2014-11-12
WO2013103792A3 (fr) 2015-01-22

Similar Documents

Publication Publication Date Title
Maverakis et al. Metastatic melanoma–a review of current and future treatment options
Butowski et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)
Moertel et al. CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy
Habashy et al. Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them
Cowawintaweewat et al. Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment
KR101183705B1 (ko) 암의 치료제
Carvalho Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial
Weide et al. Intralesional treatment of metastatic melanoma: a review of therapeutic options
Ashrafi et al. Anti-tumor effects of propranolol: Adjuvant activity on a transplanted murine breast cancer model
Gerber et al. Local expression of interleukin‐2 by B16 melanoma cells results in decreased tumour growth and long‐term tumour dormancy
AU2013249522A1 (en) Multivalent breast cancer vaccine
JP2021535083A (ja) Ｃｄ８０細胞外ドメインｆｃ融合タンパク質投与レジメン
Wang et al. Methionine enkephalin inhibits colorectal cancer by remodeling the immune status of the tumor microenvironment
Medikonda et al. Immunotherapy as a new therapeutic approach for brain and spinal cord tumors
US20210363224A1 (en) IL13Ra2 PEPTIDE AND ITS USES
US20200000899A1 (en) Pharmaceutical composition for use in the treatment of cancer
TW202128212A (zh) 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途
CA2858427A1 (fr) Procede de traitement du cancer par administration de faibles taux de proteine de choc thermique 70 (hsp70)
US20140194368A1 (en) Method of Treating Cancer by Administration of Low Levels of Heat Shock Protein 70 (HSP70)
CN105025916B (zh) 抗分泌因子(af)在胶质母细胞瘤治疗中的用途
US20190290776A1 (en) Non-adult human dosing of anti-cd30 antibody-drug conjugates
US11946094B2 (en) Combination therapies and methods of use thereof
CN101224297A (zh) 重组人血管内皮抑制素在制药中的应用
Gao et al. Tumoral IL-10-activated SHP2 in macrophages promotes mammary carcinoma progression
CN113382744A (zh) 操作脑膜淋巴管用于脑和cns肿瘤治疗

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140918

FZDE Discontinued

Effective date: 20160105